Table 5.

Prognostic factors for overall survival in the three groups after propensity score matching.

Variables	Univariate HR (95% CI)	P	Multivariate HR (95% CI)	P
Sex (male vs. female)	1.947 (0.526–7.208)	0.319
Age (≤60 vs. >60 years)	0.118 (0.034–0.409)	0.001	0.155 (0.044–0.551)	0.004
Primary Sites (stomach vs. others)	1.186 (0.375–3.752)	0.772
Metastatic phase (metachronous vs. synchronous)	0.360 (0.096–1.347)	0.129
Number of Metastases (≤3 vs. >3)	0.353 (0.095–1.306)	0.119
Largest diameter of metastases (≤3 vs. >3 cm)	0.695 (0.220–2.191)	0.534
Extrahepatic metastases (no vs. yes)	0.272 (0.086–0.860)	0.027	0.442 (0.130–1.511)	0.193
Therapy
IM alone	Reference	–	Reference	–
IM+HR	0.180 (0.022–1.495)	0.112	0.264 (0.030–2.328)	0.230
IM+RFA/TACE	0.965 (0.294–3.173)	0.953	1.022 (0.302–3.460)	0.972

HR, hazard ratio.

HR, hepatic resection; IM, imatinib; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.